Endocrine analytes in multiple-marker screening.
Prenatal serum screening is based on the observation that secretory products of the placenta and fetus are altered in maternal serum of pregnancies affected with certain birth defects. Most of these products are hormones that have been previously characterized, although the pathophysiologic basis of the altered maternal serum levels of these products that occurs in association with fetal chromosome for the most part is unknown. Prenatal serum screening is in a period of transition, with the relatively recent advance of second trimester triple-marker screening (AFP, uE3, hCG) and now the improved performance of the four-marker test that adds inhibin. A. Proposed first trimester screening and other new second trimester serum markers may dramatically change prenatal screening practices as we enter the next century.
Lambert-Messerlian
G M
GM
Department of Pathology, Brown University School of Medicine, USA.
Canick
J A
JA
D015415:Biomarkers / Q000097:blood; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D004964:Estriol / Q000097:blood*; D005260:Female; D006801:Humans; D007265:Inhibins / Q000097:blood*; D008403:Mass Screening / Q000379:methods*; D008423:Maternal Age; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000378:metabolism*; D011262:Pregnancy Trimester, Second; D011295:Prenatal Care / Q000379:methods*; D015203:Reproducibility of Results; D000509:alpha-Fetoproteins / Q000378:metabolism*
D015415:Biomarkers; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007265:Inhibins; D004964:Estriol